fondazione melanoma onlus irccs sitc patrocinio esmo regione campania Comune di Napoli

david stroncek


david stroncek
David Stroncek, MD is Chief of the Cell Processing Section (CPS) of the Department of Transfusion Medicine (DTM), Clinical Center, NIH. CPS manufactures and develops a wide variety of cellular and gene therapy products to treat Clinical Center patients. These include hematopoietic progenitors and donor lymphocytes to support hematopoietic stem cell transplantation protocols and a number of IND products for phase I/II clinical trials including dendritic cells, Natural Killer cells, genetically engineered T cells and CD34+ cells, bone marrow stromal and culture expanded T cells. Dr. Stroncek research is focused on investigating new measures of cell and gene therapy quality and potency, particularly dendritic cells and NK cells.

He has a Bachelorís of Science degree in Chemical Engineering from the University of Minnesota. He completed medical school Medical, an Internal Medicine Internship and Residency and a Hematology and Oncology Fellowship at the University of Minnesota Medical School.









For information please contact info@melanomabridge.org